

Nicholas A Vitanza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4294889/publications.pdf>

Version: 2024-02-01

63
papers

1,631
citations

394421

19
h-index

330143

37
g-index

63
all docs

63
docs citations

63
times ranked

2631
citing authors

#	ARTICLE	IF	CITATIONS
1	Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma. <i>Cancer Cell</i> , 2017, 31, 635-652.e6.	16.8	290
2	Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. <i>Cell</i> , 2020, 183, 1962-1985.e31.	28.9	177
3	Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. <i>Nature Medicine</i> , 2021, 27, 1544-1552.	30.7	138
4	Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	129
5	Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. <i>Neuro-Oncology</i> , 2019, 21, 83-94.	1.2	108
6	MR Imaging-Based Radiomic Signatures of Distinct Molecular Subgroups of Medulloblastoma. <i>American Journal of Neuroradiology</i> , 2019, 40, 154-161.	2.4	87
7	Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials. <i>Current Treatment Options in Neurology</i> , 2019, 21, 37.	1.8	73
8	EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma. <i>Oncotarget</i> , 2019, 10, 7080-7095.	1.8	52
9	Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models. <i>Neuro-Oncology</i> , 2021, 23, 376-386.	1.2	43
10	Progress in diffuse intrinsic pontine glioma: advocating for stereotactic biopsy in the standard of care. <i>Neurosurgical Focus</i> , 2020, 48, E4.	2.3	43
11	Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies. <i>Oncogene</i> , 2022, 41, 461-475.	5.9	39
12	Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. <i>Neuro-Oncology</i> , 2022, 24, 1366-1374.	1.2	36
13	The Biology of Relapsed Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, 413-418.	0.6	34
14	Pediatric Ependymoma. <i>Journal of Child Neurology</i> , 2016, 31, 1354-1366.	1.4	33
15	Deep Learning for Pediatric Posterior Fossa Tumor Detection and Classification: A Multi-Institutional Study. <i>American Journal of Neuroradiology</i> , 2020, 41, 1718-1725.	2.4	31
16	MRI Radiogenomics of Pediatric Medulloblastoma: A Multicenter Study. <i>Radiology</i> , 2022, 304, 406-416.	7.3	27
17	The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies. <i>Neuro-Oncology</i> , 2022, 24, 1408-1422.	1.2	27
18	Ikars deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1779-1785.	1.5	23

#	ARTICLE	IF	CITATIONS
19	Immunotherapy for brain tumors: understanding early successes and limitations. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 251-259.	2.8	22
20	Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience. <i>Journal of Neuro-Oncology</i> , 2020, 148, 607-617.	2.9	21
21	Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature. <i>Journal of Neuro-Oncology</i> , 2020, 147, 721-730.	2.9	21
22	MRI-based radiomics for prognosis of pediatric diffuse intrinsic pontine glioma: an international study. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab042.	0.7	14
23	The Progression of Bone Mineral Density Abnormalities After Chemotherapy for Childhood Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2015, 37, 356-361.	0.6	12
24	Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. <i>Translational Research</i> , 2017, 188, 27.e1-27.e14.	5.0	12
25	Radiomic Phenotypes Distinguish Atypical Teratoid/Rhabdoid Tumors from Medulloblastoma. <i>American Journal of Neuroradiology</i> , 2021, 42, 1702-1708.	2.4	12
26	dCas9 fusion to computer-designed PRC2 inhibitor reveals functional TATA box in distal promoter region. <i>Cell Reports</i> , 2022, 38, 110457.	6.4	12
27	Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1584-1591.	4.1	11
28	Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab169.	0.7	11
29	Integrating RNA sequencing into neuro-oncology practice. <i>Translational Research</i> , 2017, 189, 93-104.	5.0	10
30	Advances in the biology and treatment of pediatric central nervous system tumors. <i>Current Opinion in Pediatrics</i> , 2016, 28, 34-39.	2.0	9
31	STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors. <i>Journal of Clinical Oncology</i> , 2022, 40, 10011-10011.	1.6	9
32	Response to Pembrolizumab in a Patient With Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	3.0	8
33	Machine Assist for Pediatric Posterior Fossa Tumor Diagnosis: A Multinational Study. <i>Neurosurgery</i> , 2021, 89, 892-900.	1.1	8
34	Radiomic signatures of posterior fossa ependymoma: Molecular subgroups and risk profiles. <i>Neuro-Oncology</i> , 2022, 24, 986-994.	1.2	8
35	IMMU-11. CLINICAL UPDATES AND CORRELATIVE FINDINGS FROM THE FIRST PATIENT WITH DIPG TREATED WITH INTRACRANIAL CAR T CELLS. <i>Neuro-Oncology</i> , 2021, 23, i29-i29.	1.2	7
36	Considerations when treating high-grade pediatric glioma patients with immunotherapy. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 205-219.	2.8	5

#	ARTICLE	IF	CITATIONS
37	Radiomics Can Distinguish Pediatric Supratentorial Embryonal Tumors, High-Grade Gliomas, and Ependymomas. <i>American Journal of Neuroradiology</i> , 2022, 43, 603-610.	2.4	5
38	STRIVE-01: Phase I study of EGFR806 CAR T-cell immunotherapy for recurrent/refractory solid tumors in children and young adults.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2541-2541.	1.6	5
39	DIPG-35. A NOVEL HDAC INHIBITOR IN NEW PATIENT-DERIVED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) MODELS. <i>Neuro-Oncology</i> , 2018, 20, i56-i56.	1.2	3
40	A Protocol for the Generation of Treatment-naïve Biopsyderived Diffuse Intrinsic Pontine Glioma and Diffuse Midline Glioma Models. , 2020, 1, 158-167.		3
41	50 Years Ago in The Journal of Pediatrics. <i>Journal of Pediatrics</i> , 2016, 173, 100.	1.8	2
42	Pilocytic astrocytoma with leptomeningeal spread in a patient with incontinentia pigmenti presenting with unilateral nystagmus. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26886.	1.5	2
43	Molecularly Targeted Treatments for NF1-Mutant Diffuse Intrinsic Pontine Glioma. <i>journal of applied laboratory medicine, The</i> , 2021, 6, 550-553.	1.3	2
44	HGG-32. ONC201 AND ONC206 TARGET TUMOR CELL METABOLISM IN PEDIATRIC DIFFUSE MIDLINE GLIOMA PRECLINICAL MODELS. <i>Neuro-Oncology</i> , 2021, 23, i23-i24.	1.2	2
45	Two cases of pineal anlage tumor with molecular analysis. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29596.	1.5	2
46	Neonatal appendicitis presenting as a painless abdominal mass. <i>Journal of Pediatric Surgery Case Reports</i> , 2021, 72, 101964.	0.2	1
47	Care Coordination in a SARS-CoV-2-infected Child With Newly Diagnosed Medulloblastoma and Fanconi Anemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, Publish Ahead of Print, e972-e974.	0.6	1
48	Window-of-opportunity study of ONC201 in pediatric patients with diffuse intrinsic pontine glioma (DIPG) and thalamic glioma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2082-TPS2082.	1.6	1
49	50 Years Ago in The Journal of Pediatrics. <i>Journal of Pediatrics</i> , 2015, 167, 80.	1.8	0
50	Noncarboplatin-induced Sensorineural Hearing Loss in a Patient With an Intracranial Nongerminomatous Germ Cell Tumor. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 312-316.	0.6	0
51	No Further Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 969-970.	0.8	0
52	Serial plasma and CSF cell-free tumor DNA (cf-tDNA) tracking in diffuse midline glioma patients undergoing treatment with ONC201.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2012-2012.	1.6	0
53	IMMU-11. BRAINCHILD PIPELINE: LOCOREGIONAL IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RECURRENT/REFRACTORY CENTRAL NERVOUS SYSTEM TUMORS. <i>Neuro-Oncology</i> , 2018, 20, i100-i101.	1.2	0
54	ONC201 in previously irradiated pediatric H3 K27M-mutant glioma or newly diagnosed DIPG.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3619-3619.	1.6	0

#	ARTICLE	IF	CITATIONS
55	DIPG-64. INTERNATIONAL PRECLINICAL DRUG DISCOVERY AND BIOMARKER PROGRAM INFORMING AN ADOPTIVE COMBINATORIAL TRIAL FOR DIFFUSE MIDLINE GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii300-iii300.	1.2	0
56	DIPG-10. OPTIMAL HDAC INHIBITION IN DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, iii288-iii289.	1.2	0
57	TAMI-79. THERAPEUTIC REVERSAL OF PRENATAL PONTINE ID1 SIGNALING IN DIPG. <i>Neuro-Oncology</i> , 2021, 23, vi215-vi215.	1.2	0
58	Extramedullary Hematopoiesis in the Dura Mater During Treatment of a CNS Embryonal Tumor. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e1217-e1219.	0.6	0
59	IMMU-09. Interim analysis from BrainChild-03: Seattle Children's Locoregional B7-H3 CAR T Cell Trial for Children with Recurrent Central Nervous System Tumors and DIPG. <i>Neuro-Oncology</i> , 2022, 24, i83-i83.	1.2	0
60	HGG-62. Molecularly guided treatment of mismatch repair-deficient pediatric brain tumors. <i>Neuro-Oncology</i> , 2022, 24, i76-i76.	1.2	0
61	DIPG-49. International preclinical drug discovery and biomarker program informing an adoptive combinatorial trial for DMG. <i>Neuro-Oncology</i> , 2022, 24, i29-i30.	1.2	0
62	DIPG-58. Therapeutic HDAC targeting in hypermutant CNS tumors. <i>Neuro-Oncology</i> , 2022, 24, i32-i32.	1.2	0
63	LTBK-03. Targeted mass spectrometry of serial CSF and serum specimens from children with diffuse intrinsic pontine glioma treated with intracranial B7-H3 CAR T cells. <i>Neuro-Oncology</i> , 2022, 24, i191-i191.	1.2	0